Patient Safety News
Blog Home All Blogs
Search all posts for:   

 

View all (99) posts »
 

3/21 - Lidocaine Hydrochloride and 5% Dextrose Injection Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research February 2013

Posted By Administration, Wednesday, March 20, 2013
Updated: Thursday, March 21, 2013

WARNINGS

• Anaphylactic reactions may occur following administration of lidocaine hydrochloride. In the case of severe reaction, discontinue the use of the drug.

ADVERSE REACTIONS

• Hematologic Effects: methemoglobinemia

• Allergic reactions, including anaphylactic reactions


Source: U.S. Food and Drug Administration (FDA) (Accessed: 3/19/2013)

Tags:  FDA  Patient Safety 

Share |
Permalink | Comments (0)
 

Contact Us

120 E. Ogden Ave. Ste. 202
Hinsdale, Illinois 60521
P: 630.203.2252
Toll Free: 888.255.0005

© Copyright 2016 Spine Intervention Society Privacy Policy  ::  Legal